# Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie

Study · id `cardio:ct-nct03770052` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03770052](<https://clinicaltrials.gov/study/NCT03770052>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03770052

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT03770052. Randomized; double masking; primary purpose treatment. Start 2018-10-24 (actual); primary completion 2021-08-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT03770052, source copy `cardio:ctgov-nct03770052-2022-01-20`, retrieved 2026-10-26)
- Started: 2018-10-24 (actual) (ClinicalTrials.gov record NCT03770052, source copy `cardio:ctgov-nct03770052-2022-01-20`, retrieved 2026-10-26)
- Primary completion: 2021-08-19 (actual) (ClinicalTrials.gov record NCT03770052, source copy `cardio:ctgov-nct03770052-2022-01-20`, retrieved 2026-10-26)
- Completion: 2021-09-13 (actual) (ClinicalTrials.gov record NCT03770052, source copy `cardio:ctgov-nct03770052-2022-01-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03770052, source copy `cardio:ctgov-nct03770052-2022-01-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03770052-2022-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
- Condition: Type 2 Diabetes Mellitus
- Condition: Inadequate Glucose Control
- Intervention (Drug): duvie
- Lead sponsor: Pusan National University Hospital
- Lead sponsor class: OTHER
- Collaborator: Chong Kun Dang Pharmaceutical Corp.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Pusan National University Hospital (`cardio:org-pusan-national-university-hospital`)
- Registry lists this organization as a collaborator: Chong Kun Dang Pharmaceutical Corp. (`cardio:org-chong-kun-dang-pharmaceutical-corp`)

## Provenance

Content hash: 5a091ef0624a6d41a6cb9be47c51767171e63d25ac9bf5d7e2ea6ea0520cb7d2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
